Epidermal Growth Factor Receptor Mutations in the Blood of Patients With Advanced Non-Small Cell Lung Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00899756|
Recruitment Status : Completed
First Posted : May 12, 2009
Last Update Posted : February 15, 2019
RATIONALE: Collecting and storing samples of blood from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
PURPOSE: This laboratory study is looking at epidermal growth factor receptor mutations in the blood of patients with advanced non-small cell lung cancer.
|Condition or disease||Intervention/treatment|
|Lung Cancer||Genetic: molecular diagnostic method Genetic: mutation analysis|
- Determine if epidermal growth factor receptor (EGFR) mutation exists in the peripheral blood of patients with advanced non-small cell lung cancer (NSCLC).
- Estimate the frequency of EGFR mutation in these patients.
- Correlate the presence of EGFR mutation in blood with EGFR mutation in primary or metastatic NSCLC tumor block.
OUTLINE: Patients undergo blood collection for analysis of epidermal growth factor receptor mutation by DNA sequencing.
PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.
|Study Type :||Observational|
|Actual Enrollment :||50 participants|
|Official Title:||Study of Mutations of Epidermal Growth Factor Receptor in the Blood of Patients With Advanced Non Small Cell Lung Cancer|
|Actual Study Start Date :||June 2006|
|Actual Primary Completion Date :||December 2016|
|Actual Study Completion Date :||December 2016|
- Existence of epidermal growth factor receptor (EGFR) mutations in peripheral blood [ Time Frame: Day 1 ]
- Frequency of EGFR mutation [ Time Frame: Day 1 ]Number of participants with EGFR mutation in tissue and plasma.
- Number of participants with EGFR mutation in peripheral blood and in tumor tissue. [ Time Frame: Day 1 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00899756
|Singapore, Singapore, 308433|
|Study Chair:||Alex Y. Chang, MD||Johns Hopkins Singapore International Medical Centre|